At a Glance
Chemcon Speciality Chemicals just dropped its Q1 FY26 results, flaunting a ₹6.4 crore net profit (up 62% QoQ), on revenue of ₹53.5 crore (flat YoY). Margins climbed back to 14.5% OPM, but still a shadow of its once glorious 30%+ levels. With a P/E of 34.3, the stock trades like a growth darling, yet sales have been falling 5% annually. The latest buzz? A ₹100 crore acquisition of Shivam Petrochem to diversify and (hopefully) revive growth.
Introduction
Once marketed as the HMDS king of pharma intermediates, Chemcon’s growth story has been slower than a lab reaction without a catalyst. After a dream IPO, reality set in with falling revenues, eroding margins, and investors wondering if they accidentally bought the wrong specialty stock. Now, with an acquisition announcement and a new independent director on board, the company is trying to stir up some excitement. But will it mix well or just dilute shareholder value further?
Business Model (WTF Do They Even Do?)
- Products: HMDS, CMIC (key pharma intermediates) and oilfield chemicals.
- Customers: Pharmaceutical giants and oil exploration companies.
- Edge: Largest Indian manufacturer of HMDS, with high export exposure.
- Revenue Mix: 80% pharma intermediates, 20% oilfield chemicals.
Sarcasm alert: When your entire business depends on a few niche chemicals, diversification isn’t a choice – it’s survival.
Financials Overview
Q1 FY26 Highlights:
- Revenue: ₹53.5 Cr (YoY flat, QoQ -2%)
- EBITDA: ₹7.8 Cr (EBITDA margin 14.5%)
- PAT: ₹6.4 Cr (QoQ +62%)
- EPS: ₹1.74
FY25 (vs FY24):
- Revenue: ₹207 Cr (-22%)
- PAT: ₹24 Cr (+26%)
- EPS: ₹6.67
Fresh P/E Calculation: Using TTM EPS ₹6.96 → P/E = 238 / 6.96 ≈ 34.2. High, considering growth is missing.
Valuation
- P/E Method: Sector average ~25 → Fair Value ≈
